Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19582613 | 0.86 | TERT (0.55) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| Bromide SCHEMBL11347082 | 0.82 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL11348151 | 0.81 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5529492 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL11227779 | 0.80 | CYP3A4 (0.62) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL3239919 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL11350615 | 0.80 | CYP3A4 (0.62) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| Bromide SCHEMBL11346215 | 0.79 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL11345484 | 0.79 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL13995329 | 0.76 | CYP1A2 (0.54) | CYP3A4CYP2D6CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608352-B1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2009-12-30 | — | — | EP | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| WO-2008021788-A2 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (CN) | 2008-02-21 | — | — | WO | disclosed |
| EP-1608352-A4 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2007-11-28 | — | — | EP | disclosed |
| EP-1608352-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | Taigen Biotechnology (TW) | 2005-12-28 | — | — | EP | disclosed |
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2005-02-24 | — | — | US | disclosed |
| WO-2004089360-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | CCL2, CCR2, CCR5 | CYP3A4 4875/4885CYP2D6 4807/4885CYP2C9 4816/4885 |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | SRM, SMS, SMOX | CYP3A4 4877/4885CYP2D6 4861/4885CYP2C9 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.